392 related articles for article (PubMed ID: 30319631)
1. The Long Pentraxin PTX3 Is an Endogenous Inhibitor of Hyperoxaluria-Related Nephrocalcinosis and Chronic Kidney Disease.
Marschner JA; Mulay SR; Steiger S; Anguiano L; Zhao Z; Boor P; Rahimi K; Inforzato A; Garlanda C; Mantovani A; Anders HJ
Front Immunol; 2018; 9():2173. PubMed ID: 30319631
[TBL] [Abstract][Full Text] [Related]
2. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury.
Anders HJ; Suarez-Alvarez B; Grigorescu M; Foresto-Neto O; Steiger S; Desai J; Marschner JA; Honarpisheh M; Shi C; Jordan J; Müller L; Burzlaff N; Bäuerle T; Mulay SR
Kidney Int; 2018 Mar; 93(3):656-669. PubMed ID: 29241624
[TBL] [Abstract][Full Text] [Related]
3. Genetic Background but Not Intestinal Microbiota After Co-Housing Determines Hyperoxaluria-Related Nephrocalcinosis in Common Inbred Mouse Strains.
Ma Q; Grigorescu M; Schreiber A; Kettritz R; Lindenmeyer M; Anders HJ; Steiger S
Front Immunol; 2021; 12():673423. PubMed ID: 33968083
[TBL] [Abstract][Full Text] [Related]
4. Hyperoxaluria Requires TNF Receptors to Initiate Crystal Adhesion and Kidney Stone Disease.
Mulay SR; Eberhard JN; Desai J; Marschner JA; Kumar SV; Weidenbusch M; Grigorescu M; Lech M; Eltrich N; Müller L; Hans W; Hrabě de Angelis M; Vielhauer V; Hoppe B; Asplin J; Burzlaff N; Herrmann M; Evan A; Anders HJ
J Am Soc Nephrol; 2017 Mar; 28(3):761-768. PubMed ID: 27612997
[TBL] [Abstract][Full Text] [Related]
5. The gut flora modulates intestinal barrier integrity but not progression of chronic kidney disease in hyperoxaluria-related nephrocalcinosis.
Konrad L; Andersen K; Kesper MS; Kumar SV; Mulay SR; Anders HJ
Nephrol Dial Transplant; 2020 Jan; 35(1):86-97. PubMed ID: 31081025
[TBL] [Abstract][Full Text] [Related]
6. Retention of calcium oxalate crystals in renal tubules.
Khan SR; Hackett RL
Scanning Microsc; 1991 Sep; 5(3):707-11; discussion 711-2. PubMed ID: 1808708
[TBL] [Abstract][Full Text] [Related]
7. Sulforaphane elicts dual therapeutic effects on Renal Inflammatory Injury and crystal deposition in Calcium Oxalate Nephrocalcinosis.
Liu H; Yang X; Tang K; Ye T; Duan C; Lv P; Yan L; Wu X; Chen Z; Liu J; Deng Y; Zeng G; Xing J; Ye Z; Xu H
Theranostics; 2020; 10(16):7319-7334. PubMed ID: 32641994
[TBL] [Abstract][Full Text] [Related]
8. Renal tubular injury induced by ischemia promotes the formation of calcium oxalate crystals in rats with hyperoxaluria.
Cao Y; Liu W; Hui L; Zhao J; Yang X; Wang Y; Niu H
Urolithiasis; 2016 Oct; 44(5):389-97. PubMed ID: 27040948
[TBL] [Abstract][Full Text] [Related]
9. Anti-Transforming Growth Factor β IgG Elicits a Dual Effect on Calcium Oxalate Crystallization and Progressive Nephrocalcinosis-Related Chronic Kidney Disease.
Steiger S; Grill JF; Ma Q; Bäuerle T; Jordan J; Smolle M; Böhland C; Lech M; Anders HJ
Front Immunol; 2018; 9():619. PubMed ID: 29651290
[TBL] [Abstract][Full Text] [Related]
10. Calcium oxalate crystals induce renal inflammation by NLRP3-mediated IL-1β secretion.
Mulay SR; Kulkarni OP; Rupanagudi KV; Migliorini A; Darisipudi MN; Vilaysane A; Muruve D; Shi Y; Munro F; Liapis H; Anders HJ
J Clin Invest; 2013 Jan; 123(1):236-46. PubMed ID: 23221343
[TBL] [Abstract][Full Text] [Related]
11. Endogenous and exogenous pentraxin-3 limits postischemic acute and chronic kidney injury.
Lech M; Römmele C; Gröbmayr R; Eka Susanti H; Kulkarni OP; Wang S; Gröne HJ; Uhl B; Reichel C; Krombach F; Garlanda C; Mantovani A; Anders HJ
Kidney Int; 2013 Apr; 83(4):647-61. PubMed ID: 23325083
[TBL] [Abstract][Full Text] [Related]
12. Nephrocalcinosis and hyperlipidemia in rats fed a cholesterol- and fat-rich diet: association with hyperoxaluria, altered kidney and bone minerals, and renal tissue phospholipid-calcium interaction.
Schmiedl A; Schwille PO; Bonucci E; Erben RG; Grayczyk A; Sharma V
Urol Res; 2000 Dec; 28(6):404-15. PubMed ID: 11221920
[TBL] [Abstract][Full Text] [Related]
13. Evidence suggesting hyperoxaluria as a cause of nephrocalcinosis in phosphate-treated hypophosphataemic rickets.
Reusz GS; Latta K; Hoyer PF; Byrd DJ; Ehrich JH; Brodehl J
Lancet; 1990 May; 335(8700):1240-3. PubMed ID: 1971321
[TBL] [Abstract][Full Text] [Related]
14. Biology of human pentraxin 3 (PTX3) in acute and chronic kidney disease.
Speeckaert MM; Speeckaert R; Carrero JJ; Vanholder R; Delanghe JR
J Clin Immunol; 2013 Jul; 33(5):881-90. PubMed ID: 23443958
[TBL] [Abstract][Full Text] [Related]
15. Oral administration of oxalate-enriched spinach extract as an improved methodology for the induction of dietary hyperoxaluric nephrocalcinosis in experimental rats.
Albert A; Tiwari V; Paul E; Ponnusamy S; Ganesan D; Prabhakaran R; Mariaraj Sivakumar S; Govindan Sadasivam S
Toxicol Mech Methods; 2018 Mar; 28(3):195-204. PubMed ID: 28980857
[TBL] [Abstract][Full Text] [Related]
16. Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria.
Chetyrkin SV; Kim D; Belmont JM; Scheinman JI; Hudson BG; Voziyan PA
Kidney Int; 2005 Jan; 67(1):53-60. PubMed ID: 15610227
[TBL] [Abstract][Full Text] [Related]
17. Continuous infusion of oxalate by minipumps induces calcium oxalate nephrocalcinosis.
Marengo SR; Chen DH; Evan AP; Sommer AJ; Stowe NT; Ferguson DG; Resnick MI; MacLennan GT
Urol Res; 2006 Jun; 34(3):200-10. PubMed ID: 16479391
[TBL] [Abstract][Full Text] [Related]
18. Oxalobacter formigenes treatment confers protective effects in a rat model of primary hyperoxaluria by preventing renal calcium oxalate deposition.
Verhulst A; Dehmel B; Lindner E; Akerman ME; D'Haese PC
Urolithiasis; 2022 Apr; 50(2):119-130. PubMed ID: 35122487
[TBL] [Abstract][Full Text] [Related]
19. Recurrence of Hyperoxaluria and Kidney Disease after Combined Intestine-Kidney Transplantation for Enteric Hyperoxaluria.
Ekser B; Mangus RS; Kubal CA; Fridell JA; Powelson JA; Nagaraju S; Mihaylov P; Phillips CL; Saxena R; Goggins WC
Am J Nephrol; 2016; 44(2):85-91. PubMed ID: 27410399
[TBL] [Abstract][Full Text] [Related]
20. Dissecting the genetic basis of kidney tubule response to hyperoxaluria using chromosome substitution strains.
Wiessner JH; Garrett MR; Roman RJ; Mandel NS
Am J Physiol Renal Physiol; 2009 Aug; 297(2):F301-6. PubMed ID: 19493966
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
